Quarterly ResultMay 7, 2026, 04:24 PM
BioLife Solutions Q1 Revenue $27.5M, up 25%; Net Income $1.2M
AI Summary
BioLife Solutions reported strong first-quarter 2026 financial results, with total revenue increasing 25% year-over-year to $27.5 million. The company achieved GAAP net income of $1.2 million and non-GAAP adjusted EBITDA of $6.2 million. BioLife Solutions reiterated its full-year 2026 financial guidance, expecting revenue growth of 17% to 20%.
Key Highlights
- Total revenue for Q1 2026 was $27.5 million, a 25% increase from Q1 2025.
- GAAP net income for Q1 2026 was $1.2 million, up from $0.3 million in Q1 2025.
- Non-GAAP adjusted EBITDA reached $6.2 million, or 22% of revenue.
- GAAP gross margin was 64% in Q1 2026.
- Biopreservation media is used in approximately 250 U.S. clinical trials, holding over 70% market share.
- Media is embedded in 17 unique commercial cell and gene therapies.
- BioLife Solutions reiterated 2026 revenue guidance of $112.5 million to $115.0 million.
- Cash, cash equivalents, and marketable securities totaled $111.5 million as of March 31, 2026.